Dianthus Therapeutics Announces Corporate Changes
Ticker: DNTH · Form: 8-K · Filed: May 28, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-appointment, director-election, financials
TL;DR
Dianthus Therapeutics reshuffled its board and execs, filed financials. Big changes ahead?
AI Summary
Dianthus Therapeutics, Inc. announced on May 23, 2024, a series of significant corporate actions. These include the election of new directors, the appointment of certain officers, and the adoption of new compensatory arrangements. The company also reported on matters submitted to a vote of its security holders and filed financial statements and exhibits.
Why It Matters
These changes in leadership and governance structure can signal a new strategic direction or operational focus for the company.
Risk Assessment
Risk Level: medium — Changes in board composition and officer appointments can indicate strategic shifts, which carry inherent business risks.
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors or appointed officers?
The filing indicates the election of directors and appointment of officers but does not name the specific individuals in the provided text.
What specific compensatory arrangements were adopted?
The filing states that compensatory arrangements for certain officers were adopted, but the details of these arrangements are not specified in the provided text.
What matters were submitted to a vote of security holders?
The filing mentions that matters were submitted to a vote of security holders, but the specific proposals are not detailed in the provided text.
What financial statements and exhibits were filed?
The filing indicates that financial statements and exhibits were filed, but their specific content is not described in the provided text.
What was the previous name of Dianthus Therapeutics, Inc.?
The previous name of Dianthus Therapeutics, Inc. was Magenta Therapeutics, Inc., with a date of name change on November 21, 2016.
Filing Stats: 1,001 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2024-05-28 17:20:37
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
Filing Documents
- dnth-20240523.htm (8-K) — 82KB
- dnth-ex10_1.htm (EX-10.1) — 140KB
- 0000950170-24-065371.txt ( ) — 401KB
- dnth-20240523.xsd (EX-101.SCH) — 57KB
- dnth-20240523_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 23, 2024, Dianthus Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote on the five proposals set forth below, each of which is described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 11, 2024 (the "Proxy Statement"). The final voting results for the Annual Meeting are set forth below. Proposal 1 – Election of Class III Directors The Company's stockholders elected Leon O. Moulder, Jr. and Alison F. Lawton as Class III directors, to serve until the 2027 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. The votes cast at the Annual Meeting vote with respect to the election of each Class III director were as follows: Nominees For Withheld Broker Non-Votes Leon O. Moulder, Jr. 23,029,035 2,906 1,037,157 Alison F. Lawton 22,223,336 808,605 1,037,157 Proposal 2 - Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers. The results of the stockholders' vote with respect to Proposal 2 were as follows: For Against Abstain Broker Non-Votes 22,996,759 26,822 8,360 1,037,157 Proposal 3 - Advisory Vote on the Frequency of Advisory Votes on Executive Compensation The Company's stockholders recommended, by an advisory, non-binding vote, that future advisory votes to approve the compensation paid to our named executive officers be held every year. The results of the stockholders' vote with respect to Proposal 3 were as follows: One Year Two Year Three Year Abstain Broker Non-Votes 23,013,323 1,038 12,340 5,240 1,037,157 In accordance with the voting results for this
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: May 28, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary